Vhcp Management buys $5,065,724 stake in BioCryst Pharmaceuticals (BCRX)

BioCryst Pharmaceuticals (BCRX) : Vhcp Management scooped up 442,161 additional shares in BioCryst Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 1,005,104 shares of BioCryst Pharmaceuticals which is valued at $5,065,724.BioCryst Pharmaceuticals makes up approximately 4.45% of Vhcp Management’s portfolio.

Other Hedge Funds, Including , Vhcp Management Ii boosted its stake in BCRX in the latest quarter, The investment management firm added 1,031,707 additional shares and now holds a total of 5,721,142 shares of BioCryst Pharmaceuticals which is valued at $28,834,556. BioCryst Pharmaceuticals makes up approx 14.35% of Vhcp Management Ii’s portfolio. Dynamic Technology Lab Private Ltd sold out all of its stake in BCRX during the most recent quarter. The investment firm sold 19,107 shares of BCRX which is valued $96,299. Dekabank Deutsche Girozentrale sold out all of its stake in BCRX during the most recent quarter. The investment firm sold 35,000 shares of BCRX which is valued $144,900.Jennison Associates reduced its stake in BCRX by selling 1,302 shares or 0.1% in the most recent quarter. The Hedge Fund company now holds 1,356,302 shares of BCRX which is valued at $5,465,897. BioCryst Pharmaceuticals makes up approx 0.01% of Jennison Associates’s portfolio.Advisory Services Network boosted its stake in BCRX in the latest quarter, The investment management firm added 4,600 additional shares and now holds a total of 10,500 shares of BioCryst Pharmaceuticals which is valued at $35,805. BioCryst Pharmaceuticals makes up approx 0.01% of Advisory Services Network’s portfolio.

BioCryst Pharmaceuticals closed down -0.03 points or -0.72% at $4.15 with 4,77,703 shares getting traded on Monday. Post opening the session at $4.15, the shares hit an intraday low of $4.082 and an intraday high of $4.28 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, BioCryst Pharmaceuticals reported $-0.22 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.26. The company had revenue of $4.80 million for the quarter, compared to analysts expectations of $4.33 million. The company’s revenue was down -81.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.06 EPS.

Many Wall Street Analysts have commented on BioCryst Pharmaceuticals. BioCryst Pharmaceuticals was Upgraded by Piper Jaffray to ” Overweight” on Aug 12, 2016. BioCryst Pharmaceuticals was Downgraded by JMP Securities to ” Mkt Perform” on Aug 4, 2016.

BioCryst Pharmaceuticals Inc. (BioCryst) is a biotechnology company. The Company designs optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its products include RAPIVAB BCX4161 BCX7353 and other second generation HAE compounds BCX4430 and Forodesine. Peramivir is an intravenous neuraminidase inhibitor approved in multiple countries for the treatment of patients with influenza in the United States as RAPIVAB in Japan as RAPIACTA and in Korea as PERAMIFLU. BCX4161 is the Company’s Hereditary Angioedema (HAE) product candidate. BCX7353 is a plasma kallikrein inhibitor. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *